Temozolomide in Treating Patients With Brain Metastases
Phase II Treatment of Adults With Brain Metastases With Temodar
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have brain metastases.
研究概览
详细说明
OBJECTIVES:
- Determine the activity of temozolomide in patients with brain metastases.
- Determine the toxicity of this treatment in these patients.
OUTLINE: Patients are stratified according to type of primary cancer (lung carcinoma vs breast carcinoma vs malignant melanoma vs renal cell carcinoma vs colorectal carcinoma vs other).
Patients receive oral temozolomide daily on days 1-7 and 15-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 180 patients (30 per stratum) will be accrued for this study.
研究类型
阶段
- 阶段2
联系人和位置
学习地点
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- Duke Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Metastatic lesions to the brain
- Must not require immediate radiotherapy
- If received prior radiotherapy, must have progressive disease
- Evaluable disease by CT scan or MRI
- Neurologically stable
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 70-100%
Life expectancy:
- More than 12 weeks
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
Hepatic:
- Bilirubin less than 1.5 times upper limit of normal (ULN)
- SGOT or SGPT less than 2.5 times ULN
- Alkaline phosphatase less than 2 times ULN
Renal:
- Blood urea nitrogen less than 1.5 times ULN
- Creatinine less than 1.5 times ULN
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other concurrent nonmalignant systemic disease
- No acute infection requiring treatment with IV antibiotics
- HIV negative
- No frequent vomiting or medical condition that would preclude oral medication administration (e.g., partial bowel obstruction, inability to swallow)
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent hematopoietic growth factors, including epoetin alfa
- No other concurrent biologic therapy
Chemotherapy:
- At least 4 weeks since prior chemotherapy, unless evidence of disease progression
- No other concurrent chemotherapy
Endocrine therapy:
- Concurrent corticosteroids allowed if nonincreasing dose for at least 1 week prior to study
Radiotherapy:
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy to the brain, unless evidence of disease progression
- No concurrent radiotherapy
Surgery:
- At least 3 weeks since prior surgery, unless evidence of disease progression, and recovered
Other:
- No other concurrent investigational drugs
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
调查人员
- 学习椅:Henry S. Friedman, MD、Duke University
研究记录日期
研究主要日期
学习开始
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.